Literature DB >> 19793502

What is the best treatment for prediabetes?

Morali D Sharma1, Alan J Garber.   

Abstract

Worldwide, along with the increasing prevalence of obesity, the number of people with prediabetes is increasing. The diagnostic criteria for prediabetes include impaired fasting glucose, impaired glucose tolerance, and metabolic syndrome. The presence of two or more of these three criteria renders a person at high risk for future diabetes. The treatment goal of prediabetes is to prevent future development of type 2 diabetes and diabetes-related cardiovascular complications. The treatment approach is twofold: glycemic control and control of cardiovascular risk factors, mainly hypertension and hyperlipidemia. Intensive lifestyle modification is the mainstay of treatment in low-risk patients. When lifestyle modification fails and in high-risk patients, medications such as metformin and/or acarbose are recommended. For high-risk patients and those who progress despite intensive lifestyle modification, thiazolidinediones are also recommended. The goals for cardiovascular risk factor control are similar to those for patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793502     DOI: 10.1007/s11892-009-0053-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  26 in total

Review 1.  Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.

Authors:  Jean-Louis Chiasson
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

2.  Depression and anxiety with rimonabant.

Authors:  Philip B Mitchell; Margaret J Morris
Journal:  Lancet       Date:  2007-11-17       Impact factor: 79.321

3.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

4.  Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Authors:  Alan J Garber; Yehuda Handelsman; Daniel Einhorn; Donald A Bergman; Zachary T Bloomgarden; Vivian Fonseca; W Timothy Garvey; James R Gavin; George Grunberger; Edward S Horton; Paul S Jellinger; Kenneth L Jones; Harold Lebovitz; Philip Levy; Darren K McGuire; Etie S Moghissi; Richard W Nesto
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

5.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

6.  Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).

Authors:  Elizabeth L M Barr; Paul Z Zimmet; Timothy A Welborn; Damien Jolley; Dianna J Magliano; David W Dunstan; Adrian J Cameron; Terry Dwyer; Hugh R Taylor; Andrew M Tonkin; Tien Y Wong; John McNeil; Jonathan E Shaw
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

Review 7.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

8.  The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Authors:  Kristina M Utzschneider; Jenny Tong; Brenda Montgomery; Jayalakshmi Udayasankar; Fernando Gerchman; Santica M Marcovina; Catherine E Watson; Monica A Ligueros-Saylan; James E Foley; Jens J Holst; Carolyn F Deacon; Steven E Kahn
Journal:  Diabetes Care       Date:  2007-10-01       Impact factor: 19.112

9.  Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies.

Authors:  Tien Y Wong; Gerald Liew; Robyn J Tapp; Maria Inês Schmidt; Jie Jin Wang; Paul Mitchell; Ronald Klein; Barbara E K Klein; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2008-03-01       Impact factor: 79.321

Review 10.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

View more
  4 in total

1.  Effect of short duration moderate intensity physical activity on glycemic control and antioxidant status of prediabetic population.

Authors:  Zubia Shah; Inayat Shah; Muhammad O Malik; Ihsan Ullah
Journal:  Saudi Med J       Date:  2021-06       Impact factor: 1.422

Review 2.  Role of Intermittent Fasting in the Management of Prediabetes and Type 2 Diabetes Mellitus.

Authors:  Tioluwani K Ojo; Olajide O Joshua; Oboseh J Ogedegbe; Oluwapelumi Oluwole; Ayoade Ademidun; Damilola Jesuyajolu
Journal:  Cureus       Date:  2022-09-05

3.  Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Xueqin Gao; Xiaoli Hua; Xu Wang; Wanbin Xu; Yu Zhang; Chen Shi; Ming Gu
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

4.  Metformin and its clinical use: new insights for an old drug in clinical practice.

Authors:  Arrigo F G Cicero; Elisa Tartagni; Sibel Ertek
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.